← Back to Search

Kinase Inhibitor

Dabrafenib for Multiple Myeloma

Phase 1
Recruiting
Led By Noopur S Raje, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 100 weeks
Awards & highlights

Study Summary

This trial is studying how well targeted therapy works in treating multiple myeloma.

Who is the study for?
This trial is for adults with relapsed or refractory multiple myeloma, who have certain levels of monoclonal proteins in their blood or urine and have tried at least two other treatments. They should be relatively active (able to care for themselves) and not bedridden.Check my eligibility
What is being tested?
The study is testing the effectiveness of two targeted therapy drugs, Trametinib and Dabrafenib, as potential treatments for multiple myeloma. It aims to see how well these drugs work on their own or together in treating this condition.See study design
What are the potential side effects?
Trametinib and Dabrafenib can cause side effects like fever, fatigue, skin rash, nausea, heart issues, high blood pressure, bleeding problems, eye problems, liver toxicity among others. The severity of side effects varies from person to person.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~100 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 100 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate
Secondary outcome measures
Number of Participants with Severe Adverse Events

Trial Design

3Treatment groups
Experimental Treatment
Group I: TrametinibExperimental Treatment1 Intervention
Determine if mutation in BRAF, KRAS, NRAS KRAS or NRAS mutated Treat cohort with Trametinib Analysis Treat cohort with Trametinib
Group II: Dabrafenib and TrametinibExperimental Treatment2 Interventions
Determine if mutation in BRAF, KRAS, NRAS BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated Treat cohort with Dabrafenib and Trametinib Analysis Treat cohort with Dabrafenib and Trametinib
Group III: DabrafenibExperimental Treatment1 Intervention
Determine if mutation in BRAF, KRAS, NRAS BRAF V600 mutated Treat cohort with Dabrafenib Analysis Treat cohort with Dabrafenib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trametinib
FDA approved
Dabrafenib
FDA approved

Find a Location

Who is running the clinical trial?

Multiple Myeloma Research ConsortiumNETWORK
20 Previous Clinical Trials
1,298 Total Patients Enrolled
19 Trials studying Multiple Myeloma
1,245 Patients Enrolled for Multiple Myeloma
Barbara Ann Karmanos Cancer InstituteOTHER
163 Previous Clinical Trials
9,226 Total Patients Enrolled
24 Trials studying Multiple Myeloma
1,321 Patients Enrolled for Multiple Myeloma
NovartisIndustry Sponsor
1,611 Previous Clinical Trials
2,721,005 Total Patients Enrolled
24 Trials studying Multiple Myeloma
5,113 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Noopur Raje 2017. "A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03091257.
All > Multiple Myeloma
~1 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top